Skip to main content
Fig. 5 | Cancer Nanotechnology

Fig. 5

From: Synergistic action of curcumin and cisplatin on spinel ferrite/hierarchical MCM-41 nanocomposite against MCF-7, HeLa and HCT 116 cancer cell line

Fig. 5

Cytotoxic effects on several cancerous and control cell lines. Cell viability using MTT assay on A MCF7, B HeLa, C HCT116, and B HFF cell lines. Cells were treated with the following conditions for 48 h: CuFe2O4/mesosilicalite (group A), curcumin (group B), cisplatin (group C), curcumin/cisplatin (group D), CuFe2O4/mesosilicalite/curcumin (group E), CuFe2O4/mesosilicalite/curcumin/cisplatin (group F), and CuFe2O4/MCM-41/curcumin/cisplatin (group G). For groups A, E, F, and G treatment concentrations were as follows: 0.025, 0.05, 0.1, and 0.5 mg/ml. We used drug-loading experiments to calculate the concentration of adsorbed curcumin and cisplatin. Therefore, treatment concentrations of curcumin (group B) were: 0.00625, 0.0125, 0.025, and 0.125 mg/ml. Treatment concentrations of cisplatin (group C) were: 0.001125, 0.00225, 0.0045, 0.0225 mg/ml. n=5 independent experiments. Dashed line represents untreated cells control. Error bars ± S.E.M. Statistical analysis is shown in Additional file 1: Table S5

Back to article page